Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose
<p>Abstract</p> <p>Purpose</p> <p>To investigate the influence of inhomogeneity corrections on stereotactic treatment plans for non-small cell lung cancer and determine the dose delivered to the PTV and OARs.</p> <p>Materials and methods</p> <p>F...
Main Authors: | Hurkmans Coen W, Schuring Danny |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-07-01
|
Series: | Radiation Oncology |
Online Access: | http://www.ro-journal.com/content/3/1/21 |
Similar Items
-
What We Should Know in Relation to What We Do Know
by: Donald L. Rice
Published: (2014-07-01) -
Pharmaceutical Trademarks : What should we know about them?
by: Garbuz, Cristina
Published: (2017) -
Cognitive enhancers - what we should know about them
by: Andrzej Stańczak, et al.
Published: (2021-05-01) -
Weight-based dosing in medication use: what should we know?
by: Pan SD, et al.
Published: (2016-04-01) -
Determinants of Innovation Cooperation Performance: What Do We Know and What Should We Know?
by: Piotr Trąpczyński, et al.
Published: (2018-11-01)